| Page 32 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies

Author(s): 
Gorak EJ, Otterstatter M, Al Baghdadi T, Gillis N, Foran JM, Liu JJ, Bejar R, Gore SD, Kroft SH, Harrington A, Saber W, Starczynowski D, Rollison DE, Zhang L, Moscinski L, Wilson S, Thompson J, Borchert C, Sherman S, Hebert D, Walker ME, Padron E,
Primary Author: 
Gorak EJ
Journal Title: 
Blood Advances
Original Publication Date: 
Oct 2023

Myelodysplastic neoplasms (MDS) are a collection of hematopoietic disorders with widely variable prognoses and treatment options. Accurate pathologic diagnoses present challenges because of interobserver variability in interpreting morphology and quantifying dysplasia.

Bone Marrow Disease(s): 

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

Author(s): 
Mukherjee S, Dong W, Schiltz NK, Stange KC, Cullen J, Gerds AT, Carraway HE, Singh A, Advani AS, Sekeres MA, Koroukian SM
Primary Author: 
Mukherjee S
Journal Title: 
Oncologist
Original Publication Date: 
Oct 2023

Background: Older patients with

Bone Marrow Disease(s): 

Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT

Author(s): 
Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Carbacioglu S, Kenyon M, Aljurf M, Bonfim C, Makishima H, Niemeyer C, Fenaux P, Zebisch A, Hamad N, Chalandon Y, Hellström-Lindberg E, Voso MT, Mecucci C,
Primary Author: 
Gurnari C,
Journal Title: 
Lancet Hematology
Original Publication Date: 
Oct 2023

The recent application of whole exome or whole genome sequencing unveiled a plethora of germline variants predisposing to myeloid disorders, particularly myelodysplastic neoplasms. The presence of such variants in patients with

Bone Marrow Disease(s): 

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Author(s): 
Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Iannì G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P
Primary Author: 
Oliva EN
Journal Title: 
Journal of Clinical Oncology
Original Publication Date: 
Oct 2023

Purpose: In

Bone Marrow Disease(s): 

Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria

Author(s): 
Schrezenmeier H, Kulasekararaj A, Mitchell L, de Latour RP, Devos T, Okamoto S, Wells R, Popoff E, Cheung A, Wang A, Tomazos I, Patel Y, Lee JW
Primary Author: 
Schrezenmeier H
Journal Title: 
Annals of Hematology
Original Publication Date: 
Oct 2023

Bone Marrow Disease(s): 

Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia

Author(s): 
Shinn LT, Benitez LL, Perissinotti AJ, Reid JH, Buhlinger KM, van Deventer H, Barth D, Wagner CB, Zacholski K, Desai R, Soule A, Stump SE, Weis TM, Bixby D, Burke P, Pettit K, Marini BL
Primary Author: 
Shinn LT
Journal Title: 
International Journal of Hematology
Original Publication Date: 
Oct 2023

Eltrombopag has been shown to improve response rates when added to standard therapy in adults with severe

Bone Marrow Disease(s): 

Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy

Author(s): 
Kanagal-Shamanna R, Beck DB, Calvo KR
Primary Author: 
Kanagal-Shamanna R
Journal Title: 
Annual Review of Pathology: Mechanisms of Disease
Original Publication Date: 
Oct 2023

Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory diseases and myelodysplastic syndrome.

Bone Marrow Disease(s): 

Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study

Author(s): 
Fattizzo B, Gurnari C, Cassanello G, Bortolotti M, Awada H, Giammarco S, Consonni D, Sica S, Gandhi S, Trikha R, Large J, Salter S, Maciejewski JP, Barcellini W, Kulasekararaj AG
Primary Author: 
Fattizzo B
Journal Title: 
Leukemia
Original Publication Date: 
Oct 2023

Non-severe

Bone Marrow Disease(s):